Toxicokinetics 2 Crispin Pierce, Ph.D. University of Washington (206) 616-4390.

Slides:



Advertisements
Similar presentations
Karunya Kandimalla, Ph.D
Advertisements

PHARMACOKINETIC MODELS
PHARMACOKINETIC.
HLTH 340 Lecture A4 Toxicokinetic processes: Distribution (part-1)
Disposition of Chemical Compounds. Four Phases To Disposition of Chemical Compounds Absorption of Chemicals into the Body Distribution of Chemicals within.
Mathematic descript. of A) Biolog. processes affecting drugs B) Biolog. processes affected by drugs drugs Pharmacokinetics Mathematical expressions to.
1 Some Deterministic Models in Mathematical Biology: Physiologically Based Pharmacokinetic Models for Toxic Chemicals Cammey E. Cole Meredith College March.
Pharmacokinetics -- part 1 --
Pharmacotherapy in the Elderly Judy Wong
Copyright 2002 Marc Rigas Issues in Exposure Assessment Marc L. Rigas, Ph.D. National Exposure Research Laboratory, U.S. Environmental Protection Agency.
One-compartment open model: Intravenous bolus administration
Pharmacokinetics Part 1: Principles
Toxicokinetics 1 Crispin Pierce, Ph.D. University of Washington (206)
Practical Pharmacokinetics
Week 4 - Biopharmaceutics and Pharmacokinetics
Pharmacokinetics Based on the hypothesis that the action of a drug requires presence of a certain concentration in the fluid bathing the target tissue.
Species extrapolation with PBPK models
Approaches for Evaluating the Relevance of Multiroute Exposures in Establishing Guideline Values for Drinking Water Contaminants Kannan Krishnan, Université.
VM 8314 Dr. Jeff Wilcke Pharmacokinetic Modeling (describing what happens)
© 2004 by Thomson Delmar Learning, a part of the Thomson Corporation. Fundamentals of Pharmacology for Veterinary Technicians Chapter 4 Pharmacokinetics.
The General Concepts of Pharmacokinetics and Pharmacodynamics Hartmut Derendorf, PhD University of Florida.
Nonlinear Pharmacokinetics
Analytical Toxicology Pharmacokinetics and Pharmacodynamics.
Pharmacokinetics Introduction
Lecture 2.  Clearance Ability to eliminate the drug  Volume of distribution (Vd) The measure of the apparent space in the body available to contain.
Federal Aviation Administration Handheld Advisory Circular Update Louise Speitel Fire Safety Branch FAA Wm. J. Hughes Technical Center Atlantic City International.
A Physiological Based Description of the Inhalation Pharmacokinetics of Styrene in Rats and Humans John C. Ramsey and Melvin E. Andersen Toxicology and.
From A Physiologic Perspective Chemical Clearance from the Body
Animal Studies and Human Health Consequences Sorell L. Schwartz, Ph.D. Department of Pharmacology Georgetown University Medical Center.
Chapter 4 Pharmacokinetics Copyright © 2011 Delmar, Cengage Learning.
Basic Pharmacokinetics The time course of drug action Collected and Prepared By S.Bohlooli, PhD.
PHARMACOKINETIC MODELS
Touqeer Ahmed Ph.D. Atta-ur-Rahman School of Applied Bioscience, National University of Sciences and Technology 21 st October, 2013.
MECHANISTIC PHARMACOKINETICS: COMPARTMENTAL MODELS
Biopharmaceutics refers to the relationship of the:
Drug Administration Pharmacokinetic Phase (Time course of ADME processes) Absorption Distribution Pharmaceutical Phase Disintegration of the Dosage Form.
Core Concepts in Pharmacology Chapter 5 Pharmacokinetics.
The General Concepts of Pharmacokinetics and Pharmacodynamics
!!!……Molecular Target Concept A gonist Antagonist.
1 Some Deterministic Models in Mathematical Biology: Physiologically Based Pharmacokinetic Models for Toxic Chemicals Cammey E. Cole Meredith College January.
INTRODUCTION CLINICAL PHARMACOKINETICS
Toxicokinetics 3 - Computer Exercises Crispin Pierce, Ph.D. University of Washington (206)
NUATRC/TCEQ Air Toxics Workshop October Air Toxics Air Toxics: What We Know, What we Don’t Know, and What We Need to Know Human Health Effects –
Development of a Physiologically Based Pharmacokinetic and Pharmacodynamic Model to Quantitate Biomarkers of Exposure to Organophosphorus Insecticides.
PHT 415 BASIC PHARMACOKINETICS
The General Concepts of Pharmacokinetics and Pharmacodynamics
Clearance: basic concept (in vitro) Update OCT 2010.
415 PHT Plasma Level – Time Curve
1 Biopharmaceutics Dr Mohammad Issa Saleh. 2 Biopharmaceutics Biopharmaceutics is the science that examines this interrelationship of the physicochemical.
1 CHAPTER 2 DEFINITIONS RELATED TO PHARMACOKINETICS.
Foundation Knowledge and Skills
Source: Frank M. Balis Concentration and Effect vs. Time Conc./ Amount Effect [% of E MAX ] Time Central Compartment Peripheral Compartment Effect Compartment.
Drug Response Relationships
Pharmacokienetic Principles (2): Distribution of Drugs
Physiology for Engineers
Pharmacology Phone Number: (203)
Applications of Pharmacokinetics
Chapter 1 Introduction to Biopharmaceutics & Pharmacokinetics
Quantitative Pharmacokinetics
Kinetics, Modeling Oct 19, 2009 Casarett and Doull,
Biopharmaceutics Dr Mohammad Issa Saleh.
Dosimetry and Kinetics
Kinetics, Modeling Oct 15, 2006 Casarett and Doull,
Food Chemicals Toxicity
Hawler Medical University
Therapeutic Drug Monitoring chapter 1 part 1
Project #1: Drug Kinetics in Genetically Modified Mice
Presentation transcript:

Toxicokinetics 2 Crispin Pierce, Ph.D. University of Washington (206)

Purposes of Toxicokinetics zTo quantify toxicant absorption, distribution, metabolism, and excretion (ADME). zTo provide an exposure framework for risk assessment.

The Value of Modeling zUnderstand biologic systems zDrive data collection zInterpolate zExtrapolate zPredict zReduce animal usage

? zModels are an abstraction of reality. To establish dose-risk relationships, we can choose anything between a completely theoretical model, and massive testing of humans to toxic chemicals. What are the hallmarks of a model/testing paradigm that you would mandate?

Four Modeling Approaches zHand-Waving zNon-Compartmental zCompartmental zPhysiologic

Hand Waving zThe same dose/kg gives the same blood concentration. zUse a 10-fold safety factor for test animal- human differences. zUse a 10-fold safety factor for interindividual differences. zUse a 1-10-fold modifying factor for additional uncertainties.

? zFor what kinds of substances, exposures, and test costs would the hand-waving approach be appropriate?

Non-Compartmental Models zEmpiric observation of volume, clearance, and half-life. zNo structural model of where the toxicant goes. AUC Time Blood (or plasma ) Concen tration CL = F·Dose/AUC

Compartmental Models zBody is viewed as distinct "compartments," which are interconnected by rate constants. zModeling is empiric, and compartments do not directly correspond to tissues. zComplete flexibility in fitting model parameters to observed data. Use of minimum number of compartments that adequately describe the data.

One Compartment Model zOne compartment model: xenobiotic distributes into a single, homogenous "vessel" (example: methanol).

? zHow would you define an adequate fit of your model to the data?

Two Compartment Model zTwo compartment model: xenobiotic distributes into a central, and then a peripheral compartment.

zRate of change of toxicant in central compartment = ka*Amount at absorption site - k12*Amount in Central Compartment + k21*Amount in Peripheral Compartment - k10*Amount in Central Compartment ka

zt 1/2,  = ln2/ , t 1/2,  = ln2/  zAUC = A/  + B/  zt 1/2, , t 1/2, , , and  are constant with dose. zA and B vary with dose. Time ln Conc i.v. dose A B slope = -  

? zHow would you test whether the kinetics of a chemical is better described by one or two compartments?

Physiologically-Based Kinetic (PBK) Modeling zAn attempt to simulate toxicant disposition in the body by using measured values: yTissue volumes and blood flows yToxicant-specific tissue partition coefficients and elimination rates

zBody is viewed as grouped tissue compartments which are interconnected by blood flows. zModeling is mechanistic, and compartments are defined by physiologic volumes and partition coefficients. zModel parameters are fit within physiologic bounds to observed data. Use of minimum number of compartments that adequately describe the data.

Lung Blood Q t Cven Q t = CO Cart Cva Q a =.09*CO Cvr Qr=.49 *CO Cvs Qs=.15 *CO Cvl Ql=.25 *CO Rapidly Perfused Tissues Slowly Perfused Tissues Adipose Tissues IV, dermal dose Oral Dose Liver Inhalation dose

Flow-Limited Delivery zFlow-limited delivery of xenobiotics to tissue groups: where: A t = Amount in tissue, Q t = Blood flow to tissue, C a = Arterial blood concentration, K p = Tissue/blood partition coefficient, V t = Tissue volume

Michaelis-Menten Metabolism V max = Maximum metabolic rate, K m = Michaelis constant (toxicant concentration at half-maximum metabolic rate)

? zWhich kind of model would you use to study identical dosing in a very homogeneous group (e.g., vaccinations in two year-olds)? zWhich kind of model would you use to study varied dosing in a heterogeneous group (e.g., genetically modified food in the general population)?

Uses of the PBK Model zUse across a wide range of doses - low to saturating. zInterspecies scaling, in particular with regards to risk. zDetermination of target tissue dose. zSimulating complex risk assessment conditions. zSearching for relevant interindividual differences.

Toxicant-Specific Considerations zMolecular weight, conformation, charge >>> Flow- or diffusion-limited delivery and filtration by kidney. zVapor pressure over blood >>> Elimination by exhalation. zMolecular weight, conformation, charge (lipophilicity) >>> Tissue distribution and accumulation.

Human Physiologic Considerations zGenetic polymorphism >>> Metabolic rates zSex and age differences >>> Blood flows and metabolic rates zWeight >>> Blood flows and tissue volumes zBody fat percentage >>> Adipose tissue volume zWorking conditions >>> Alveolar ventilation rate, cardiac output, blood flows zRoute of administration >>> First-pass effects

? zWhich PBK model parameters are likely known with greatest certainty? Which with least certainty? Which would you allow to vary within physiologic bounds to describe the data? zMight the PBK model be used to question the accuracy of data between studies?